Benzinga | Apr 28, 2021 08:26AM EDT

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for the Treatment of Bullous Pemphigoid

* A multicenter Phase III study of nomacopan for the treatment of moderate and severe bullous pemphigoid (BP) has been initiated

* Nomacopan has potential to replace long term steroid treatment (standard of care) in BP, which has multiple adverse effects and increases mortality in this elderly and frail population

* Recently announced U.S. Food and Drug Administration (FDA) approval of the Investigational New Drug Application (IND) enables clinical sites to be opened in the U.S. Clinical sites are planned to open in Europe mid-2021.